Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 320c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $89.41 --0%
Financial Fact:
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES: -19.42M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES: -19.42M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of $2.75, $3.20 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $542.71 million versus the consensus estimate of $127.9 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Nlight (LASR) Reiterated at Buy by Stifel: Sell-off is a 'Buying Opportunity'
- Deere shares climb as fiscal Q3 earnings and revenue top estimates
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
